Mouse Monoclonal GRIA3 Antibody

The GRIA3 gene encodes the GluA3 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are ionotropic glutamate receptors critical for fast excitatory synaptic transmission in the central nervous system. AMPA receptors are tetrameric complexes composed of GluA1-4 subunits, with GluA3 playing a key role in synaptic plasticity, learning, and memory. Antibodies targeting GRIA3/GluA3 are essential tools for studying the expression, localization, and function of this subunit in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate GluA3 distribution in neuronal tissues, its trafficking to postsynaptic membranes, and its involvement in long-term potentiation (LTP) or depression (LTD). Dysregulation of GluA3 has been linked to neurological disorders, including epilepsy, Alzheimer’s disease, and schizophrenia, making GRIA3 antibodies valuable for exploring disease mechanisms. Researchers also utilize these antibodies to study GluA3-specific interactions with auxiliary proteins (e.g., TARPs) and post-translational modifications (e.g., phosphorylation) that modulate receptor activity. Commercial GRIA3 antibodies are typically validated for specificity against recombinant proteins or knockout controls to ensure accurate detection of splice variants or phosphorylated states. Ongoing research continues to clarify GluA3's unique contributions to AMPA receptor diversity and its potential as a therapeutic target.